Methylomic analysis identifies C11orf87 as a novel epigenetic biomarker for GI cancers

Abstract

Gastric cancer is one of the leading causes of cancer death worldwide. Previous studies demonstrated that activation of STAT3 is crucial for the development and progression of gastric cancer. However, the role of STAT3 in neuronal related gene methylation in gastric cancer has never been explored. In this study, by using DNA methylation microarray, we identified a potential STAT3 target, C11orf87, showing promoter hypomethylation in gastric cancer patients with lower STAT3 activation and AGS gastric cancer cell lines depleted with STAT3 activation. Although C11orf87 methylation is independent of its expression, ectopic expression of a constitutive activated STAT3 mutant upregulated its expression in gastric cancer cell line. Further bisulfite pyrosequencing demonstrated a progressive increase in DNA methylation of this target in patient tissues from gastritis, intestinal metaplasia, to gastric cancer. Intriguingly, patients with higher C11orf87 methylation was associated with better survival. Furthermore, hypermethylation of C11orf87 was also frequently observed in other GI cancers, as compared to their adjacent normal tissues. These results suggested that C11orf87 methylation may serve as a biomarker for diagnosis and prognosis of GI cancers, including gastric cancer. We further postulated that constitutive activation of STAT3 might be able to epigenetically silence C11orf87 as a possible negative feedback mechanism to protect the cells from the overactivation of STAT3. Targeted inhibition of STAT3 may not be appropriate in gastric cancer patients with promoter hypermethylation of C11orf87.

Oncogenic Potential of Replication Factor C Subunit 4: Correlations with Tumor Progression and Assessment of Potential Inhibitors

“…Cancer initiation is commonly instigated by several forms of epigenetic alterations that ultimately inactivate tumor suppressor genes and activate oncogenes [ 61 ]. DNA methylation represents a prominent epigenetic critical process [ 62 ]. Therefore, we utilized two platforms, UALCAN [ 63 ] and [ 64 ] SMART app, to examine the DNA methylation state of RFC4 in the presence of tumor conditions and make a comparison with normal controls.…”

ACTL6A: unraveling its prognostic impact and paving the way for targeted therapeutics in carcinogenesis

“…The initiation of cancer frequently involves various epigenetic alterations that lead to the deactivation of genes restraining tumor growth and the activation of genes promoting cancer development ( Qu et al, 2013 ). A pivotal epigenetic process in this context is DNA methylation ( Tran et al, 2021 ). To explore the DNA methylation status of ACTL6A in tumor settings and make comparisons with normal controls, we employed two platforms: UALCAN ( Chandrashekar et al, 2022 ) and SMART app ( https://bio.tools/SMART_App# ) ( Li et al, 2019 ).…”

Integration of Chemoinformatics and Multi-Omics Analysis Defines ECT2 as a Potential Target for Cancer Drug Therapy

“…DNA methylation is an established approach for cellular control of specific gene expression [ 29 ], where a hypomethylation status of oncogene allows for its elevated expression and finally cancer progression [ 30 ]. The current study employed 2 web servers—UALCAN [ 31 ] and SMART app [ 32 ]—to investigate the methylation status of ECT2 in tumor versus normal samples.…”